SPX3,933.92-7.34 -0.19%
DIA336.44-0.02 -0.01%
IXIC10,958.55-56.34 -0.51%

BRIEF-Canbridge Pharmaceuticals Says Granted Orphan Drug Designation For CAN 106 For Treatment Of Myasthenia Gravis By The U.S. FDA

Reuters · 11/15/2022 20:07
BRIEF-Canbridge Pharmaceuticals Says Granted Orphan Drug Designation For CAN 106 For Treatment Of Myasthenia Gravis By The U.S. FDA

- Canbridge Pharmaceuticals Inc 1228.HK:

  • CANBRIDGE PHARMACEUTICALS INC- GRANTED ORPHAN DRUG DESIGNATION FOR CAN 106 FOR TREATMENT OF MYASTHENIA GRAVIS BY THE U.S. FDA

Source text for Eikon: ID:

Further company coverage: 1228.HK


((Reuters.Briefs@thomsonreuters.com;))